Cryoport

CYRX
19.0502.56% ( -0.500 )
Closed: Nov 20, 16:00:00 (EDT)

Financials

Q3 FY2026 EarningsQ3 FY26 results beat consensus on the top line with revenue of $50.2M vs. $48.7M expected, driven by 20% YoY growth in commercial Cell and Gene Therapy (CGT). Adjusted EBITDA turned positive to $1.1M, marking a key milestone in the pathway to profitability. However, GAAP EPS of -$0.25 missed the -$0.18 consensus due to investment valuation adjustments. Management raised full-year 2026 revenue guidance to $197M–$199M, signaling strong demand across its integrated life sciences platform.

Financial report interval: 2026.06.30 - 2026.09.30

Overview: Cryoport(CYRX) the Revenue is 50.22 M (+13.54%), Beat estimate;the EBIT is -8.804 M (+11.36%), Beat estimate;the EPS is -0.25 (-38.89%), Miss estimate.

Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.05B13.54%
0.05B10.07%
+0.00B3.47%
EBITExceed expectations
-0.01B11.36%
-0.01B5.04%
+0.00B6.32%
EPSMiss expectations
-0.2538.89%
-0.17751.39%
-0.072540.28%

Upcoming earnings report - FY2026 Annual Earning Release

Available dateMar 3, 2027
Estimate Revenue198.05M
Estimate EBIT-37.01M
Estimate EPS-0.8633

Revenue

ActualEstimateUnit: USD
Quarterly

EBIT

ActualEstimateUnit: USD
Quarterly

Net income

ActualEstimateUnit: USD
Quarterly

EPS

ActualEstimateUnit: USD
Quarterly